Results 11 to 20 of about 5,546 (214)

Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study [PDF]

Frontiers in Endocrinology
IntroductionAcromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.ObjectivesTo ...
Eva Venegas Moreno, Eva Venegas Moreno, Andrés Jiménez-Sánchez, Andrés Jiménez-Sánchez, Pablo Remón-Ruiz, Pablo Remón-Ruiz, Elena Dios, Elena Dios, Jaime Perea Cortés, Celia Hernández-Reina, David A. Cano, Alfonso Soto Moreno, Alfonso Soto Moreno   +12 more
doaj   +2 more sources

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study [PDF]

Frontiers in Endocrinology
IntroductionPasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing’s disease (CD). Hyperglycemia during treatment can occur because of the drug’s mechanism of action, although treatment discontinuation is rarely ...
Ulla Feldt-Rasmussen, Ulla Feldt-Rasmussen, Marek Bolanowski, Shao-Ling Zhang, Yerong Yu, Przemysław Witek, Pramila Kalra, Noppadol Kietsiriroje, Andrea Piacentini, Alberto M. Pedroncelli, Susan L. Samson   +10 more
doaj   +2 more sources

A prospective longitudinal study of Pasireotide in Nelson's syndrome [PDF]

, 2018
PURPOSE: Nelson's syndrome is a challenging condition that can develop following bilateral adrenalectomy for Cushing's disease, with high circulating ACTH levels, pigmentation and an invasive pituitary tumor. There is no established medical therapy.
A Colao, A Colao, A Colao, A Colao, A Dornhorst, A Lacroix, A Munir, AA Kasperlik-Zaluska, AN Elias, Ashley B. Grossman, B Ambrosi, Constantine Girio-Fragkoulakis, CS Graffeo, DH Nelson, Eleni Daniel, G Assie, G Assie, G Gwinup, I Shimon, I Shraga-Slutzky, IL Wapnir, J Marek, John Newell-Price, K Hayashi, L Katznelson, L Kvols, LA Casulari, LJ Hofland, M Andreassen, M Reincke, Miguel Debono, MJ Levy, P Loli, PA Kelly, Peter J. Trainer, PJ Jenkins, R Pivonello, R Pivonello, RA Feelders, RR Henry, Scott A. Akker, Sharon Caunt, Stephen J. Walters, SW Lamberts, VJ Moyes, WJ Mauermann   +45 more
core   +3 more sources

Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment [PDF]

Scientific Reports
Pasireotide frequently causes severe hyperglycemia; however, its detailed mechanism remains unknown. There are no published guidelines regarding the optimal management of pasireotide-induced hyperglycemia based on its pathophysiology.
Junichiro SATO, Katsunori MANAKA, Hirofumi HORIKOSHI, Maho TAGUCHI, Kazuki HARADA, Takashi TSUBOI, Masaomi NANGAKU, Taroh IIRI, Noriko MAKITA   +8 more
doaj   +2 more sources

Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal [PDF]

Frontiers in Endocrinology
Pasireotide is an effective treatment for both Cushing’s disease (CD) and acromegaly due to its ability to suppress adrenocorticotropic hormone and growth hormone, and to normalize insulin-like growth factor-1 levels, resulting in tumor shrinkage ...
Przemysław Witek, Marek Bolanowski, Adam Krętowski, Aleksandra Głowińska   +3 more
doaj   +2 more sources

Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature

Clinical Case Reports, 2022
Insulinomas are rare neuroendocrine pancreatic tumors that can be associated with severe episodes of hypoglycemia, leading to significant morbidity and mortality.
Hasan Husni, Sara A. Khan, Buraq Alghaieb, Mohammed S. Abusamaan, Thomas W. Donner, Amir H. Hamrahian   +5 more
doaj   +2 more sources

Management of patients with Cushing’s disease in the Gulf Region: a Delphi consensus recommendation [PDF]

Frontiers in Endocrinology
IntroductionCushing’s disease (CD), most commonly caused by ACTH-secreting pituitary adenomas, is a rare but serious endocrine disorder characterized by chronic hypercortisolism.
Mussa H. Almalki, Mussa H. Almalki, Tarik Elhadd, Khaled M. AlDahmani, Khaled M. AlDahmani, Khaled M. AlDahmani, Aishah Ekhzaimy, Abdullah Alqanaei, Hasan F. Jamal, Abdulla Alfutaisi, Moeber Mahzari, Moeber Mahzari, Moeber Mahzari, Salem A. Beshyah, Salem A. Beshyah, Ali S. Alzahrani, Ali S. Alzahrani, Ali S. Alzahrani   +17 more
doaj   +2 more sources

Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study. [PDF]

J Clin Med
Dzialach L, Respondek W, Witek P.
europepmc   +3 more sources

Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2021
ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases.
Christiaan F. Mooij, Carline E. Tacke, Mirjam E. van Albada, Winfried Barthlen, Hennie Bikker, Klaus Mohnike, Matthijs W.N. Oomen, A.S. Paul van Trotsenburg, Nitash Zwaveling-Soonawala   +8 more
doaj   +1 more source

Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar. [PDF]

Case Rep Endocrinol
Background Acromegaly, a rare endocrine disorder characterised by excess growth hormone (GH) and insulin‐like growth factor 1 (IGF‐1), is often due to GH‐secreting pituitary adenomas. Pasireotide, a second‐generation somatostatin receptor ligand (SRL), binds to multiple somatostatin receptors (SSTRs) and offers a promising alternative for patients ...
Elhadd T, Dabbous Z, Abdelmahmuod EA, Rohani Z, Kailani YA.   +4 more
europepmc   +2 more sources